Alaya.bio, founded in Cambridge, Massachusetts, is a pioneering biotechnology company focused on advancing in situ gene delivery platforms, particularly for CAR T cell immunotherapy. The company's core mission is to enhance the precision and efficiency of therapeutic payload delivery, including viral vectors and nucleic acids like mRNA. Alaya.bio's proprietary polymeric delivery nanoparticles are designed to target specific cells and organs, significantly improving the transduction efficiency of quiescent cells such as T-cells and NK-cells while maintaining their naive and memory phenotypes. Their products can be used both ex vivo and in vivo, catering to a broad market within the biotechnology and medical research sectors.

Notable figures affiliated with Alaya.bio include leading scientists and industry experts in gene therapy and immunotherapy. The company has attracted significant interest from investors specializing in biotech innovations. Key achievements include the development of their proprietary nanoparticle technology, which has shown promising results in preclinical studies. Alaya.bio's impact is marked by its potential to revolutionize gene therapy delivery methods, offering more effective treatments for various diseases and advancing the field of CAR T cell immunotherapy.